Biotech Values

[DewDiligence]

ADH CC:

There was nothing really new, but CEO William Peters gave a nice synopsis of ADH’s programs with ADH-1 and Eniluracil. However, I doubt that many were listening. This company is still very far below Wall Street’s radar screen.

(On the other hand, ADH is one of the few green stocks on my screen today, so perhaps a few people actually were listening.)

The CFO projected a cash burn rate of $1-1.5M per month and asserted that the existing cash balance will be sufficient to get through 2Q07. By then, hopefully GSK will have exercised its option to license ADH-1, in which case the ADH’s liquidity concerns will no longer be concerns.